Literatur
- 1
Dormandy J A. et al .
Secondary Prevention of macrovascular events in patients with type 2 diabetes in the
PROactive Study.
Lancet.
2005;
366
1279-1289
- 2
Drucker D, Nauck M A.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4
inhibitors in type 2 diabetes.
Lancet.
2006;
368
1696-1705
- 3
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators .
Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes
mellitus: results of the HOPE study and MICRO HOPE substudy.
Lancet.
2000;
355
253-259
- 4
Iranmanesh A, Rosenstock J. et al. on behalf of the SERENADE study group .
SERENADE: Rimonabant monotherapy for treatment of multiple cardiometabolic risk factors
in treatment-naïve patients with type 2 diabetes (Abstract 637b).
Diabetic Medicine.
2006;
23
(Suppl 4)
230
- 5
Kahn S E. et al .
Glycemic durability of Rosiglitazone, Metformin, or Glyburide monotherapy.
N Engl J Med.
2006;
355
2427-2443
- 6
Nissen S E, Wolski K.
Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular
causes.
N Engl J Med.
2007;
356
, May 21 [Epub ahaed of print]
- 7
Scheen A J, Finer N. et al. .
Efficacy and tolerability of rimonabant in overweight or obese patients with type
2 diabetes: a randomized controlled trial.
Lancet.
2006;
368
1660-1672
- 8
Scherbaum W A. im Auftrag der DDG (Hrsg) .
Praxis-Leitlinien der Deutschen Diabetes-Gesellschaft.
Diabetologie und Stoffwechsel.
2007;
(Suppl 2)
2
143-220
- 9
The DREAM (Diabetes REduction Assessment with amipril and rosiglitazone Medication)
Trial Investigators .
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose
tolerance or impaired fasting glucose: a randomized controlled trial.
Lancet.
2006;
368
1096-1105
- 10
The Task Force on Diabetes and Cardiovascular Diseases of the European Society of
Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary.
Eur Heart J.
2007;
28
88-136
Prof. Dr. med. W. A. Scherbaum
Direktor der Klinik für Endokrinologie, Diabetologie und Rheumatologie, Universitätsklinikum
Düsseldorf
Moorenstr. 5
40225 Düsseldorf
Phone: 0211/81-17810
Fax: 0211/81-17860
